北京怡和嘉业医疗科技股份有限公司 关于回购公司股份进展的公告 证券代码：301367 证券简称：怡和嘉业 公告编号：2024-060 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 北京怡和嘉业医疗科技股份有限公司（以下简称"公司"）于 2024 年 4 月 11 日召开公司第三届董事会第七次会议和第三届监事会第七次会议，审议通过 《关于回购公司股份方案的议案》。回购股份的实施期限为自公司董事会审议通 过回购方案之日起不超过 12 个月。 具体内容详见公司于 2024 年 4 月 12 日、2024 年 4 月 13 日、2024 年 4 月 20 日刊登在巨潮资讯网（www.cninfo.com.cn）上的《关于回购公司股份方案的 公告》（2024-020）、《关于回购股份事项前十大股东和前十大无限售条件股东 持股情况的公告》（2024-025）、《回购报告书》（2024-026）。 根据《上市公司股份回购规则》、《深圳证券交易所上市公司自律监管指引 第 9 号——回购股份》等相关规定，公司应当在每个月的前 3 个交易日内披露截 至上月末的回购进展情况。现将 ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The report highlights that the U.S. market has shown signs of a turning point in Q3 2024, with a continuous improvement in revenue structure. The company achieved a revenue of 602 million yuan in the first three quarters of 2024, a year-on-year decrease of 36.31%, and a net profit attributable to the parent company of 125 million yuan, down 53.74% year-on-year. However, Q3 alone saw a revenue increase of 10.51% year-on-year, reaching 220 million yuan, and a net profit of 32.74 million yuan, up 21.78% year-on-year [1][2] Summary by Relevant Sections Financial Performance - In the first three quarters of 2024, the company's international business revenue was 365 million yuan, accounting for 60.55% of total revenue, while domestic business revenue was 238 million yuan, accounting for 39.45%. The overseas revenue in Q3 reached 146 million yuan, with an increased share of 66.36% compared to the first half of 2024, largely due to the recovery of orders from RH since the end of June [1] - The company's revenue projections for 2024-2026 are 916 million yuan, 1.079 billion yuan, and 1.275 billion yuan, with growth rates of -18.4%, 17.8%, and 18.2% respectively. The net profit attributable to the parent company is expected to be 220 million yuan, 292 million yuan, and 373 million yuan for the same period, with growth rates of -26.0%, 32.8%, and 27.8% respectively [2][4] Business Segments - The home respiratory machine treatment business generated 375 million yuan in revenue, accounting for 62.27% of total revenue, while consumables revenue was 206 million yuan, accounting for 34.16%. The consumables business saw a year-on-year growth of 31.77%, primarily driven by contributions from the U.S. and European markets [1][2] Profitability - The company's gross margin for the first three quarters of 2024 was 51.20%, an increase of 4.91 percentage points year-on-year. The high-margin consumables business is expected to continue to grow, further enhancing profitability [1][2]

Investment Rating - The report assigns a "Buy" rating for the company, marking its first coverage [2]. Core Views - The company has signed a five-year exclusive distribution agreement with 3B Medical, Inc. for the sale of sleep apnea treatment devices in the U.S. and Canada, which is expected to improve overseas order trends [4][7]. - The company reported a revenue of 602 million yuan for the first three quarters of 2024, a year-on-year decline of 36.31%, but showed signs of recovery with a 10.51% increase in revenue for the third quarter compared to the previous year [3][7]. - The report anticipates significant growth in U.S. orders due to the recovery of 3B Medical's order volume to industry norms and the introduction of new products [4][7]. Summary by Sections Company Overview - Latest closing price: 75.79 yuan - Total shares: 0.90 billion, circulating shares: 0.57 billion - Total market capitalization: 6.8 billion yuan, circulating market capitalization: 4.3 billion yuan - 52-week high/low: 126.50/56.99 yuan - Debt-to-asset ratio: 4.5% - Price-to-earnings ratio: 16.30 [1]. Financial Performance - For Q3 2024, the company achieved a net profit of 32.74 million yuan, a year-on-year increase of 21.78% [3]. - The company expects revenues of 926 million yuan, 1.243 billion yuan, and 1.442 billion yuan for 2024, 2025, and 2026 respectively, with corresponding growth rates of -17.5%, 34.2%, and 16.0% [7][8]. Market Strategy - The company has tailored its sales strategies for different regions, including establishing a consumables team in the U.S. and expanding its services in Europe through a new subsidiary [5]. - The report highlights the increasing public awareness of obstructive sleep apnea (OSA) health management, driven by advancements in wearable technology [5][6]. Earnings Forecast - The company is expected to see a turnaround in performance, with projected net profits of 230 million yuan, 307 million yuan, and 375 million yuan for 2024, 2025, and 2026, respectively [7][8].

国泰君安版权所有发送给上海东方财富金融数据服务有限公司.东财接收研报邮箱.ybjieshou@eastmoney.com p1 | --- | |-------| | | | | | | 公 司 更 新 报 告 证 券 研 究 报 告 ——怡和嘉业 2024Q3 业绩点评 业绩符合预期，环比有望持续改善 怡和嘉业(301367) [Table_Industry] 医药/必需消费 | --- | --- | --- | --- | --- | |-----------------|-------------------|-------|-------|--------------------------| | | | | | | | [table_Authors] | 丁丹 ( 分析师 ) | | | 张拓 ( 分析师 ) | | | 0755-23976735 | | | 0755-23976170 | | | dingdan@gtjas.com | | | zhangtuo024925@gtjas.com | | 登记编号 | S0880514030001 | | | S0880523090003 | 本报 ...

证券代码：301367 证券简称：怡和嘉业 北京怡和嘉业医疗科技股份有限公司 投资者关系活动记录表 编号：2024—013 | --- | --- | --- | |----------------|-------------------------------|----------------------------------------------------------| | | □ 特定对象调研 □ | 分析师会议 | | 投资者关系活动 | □ 媒体采访 | √ 业绩说明会（电话形式） | | 类别 | □ 新闻发布会 □ | 路演活动 | | | □ 现场参观 | | | | □ 其他 | | | 参与单位名称 | 详见附件清单 | | | 时间 | 2024 年 10 月 25 日 | | | 地点 | 电话会议 | | | 上市公司接待人 | 副总经理兼董事会秘书：杜祎程 | | | 员姓名 | 副总经理兼财务总监：暴楠 | | | | 证券事务代表：刘士岩 | | | | 一、公司简要介绍 | | | | 公司 2001 年成立， | 2003 年第一台多导睡眠检测仪上市， 2007 | ...

出席本次业绩说明会的人员拟定为：公司董事长兼总经理庄志先生、副总经理兼董 事会秘书杜祎程先生。具体以当天实际参加会议人员为准。 证券代码：301367 证券简称：怡和嘉业 公告编号：2024-059 北京怡和嘉业医疗科技股份有限公司 关于举行2024年第三季度网上业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 北京怡和嘉业医疗科技股份有限公司（以下简称"公司"）于 2024 年 10 月 25 日 发布了《2024 年第三季度报告》，并披露于中国证监会指定的创业板信息披露网站巨潮 资讯网（http://www.cninfo.com.cn）。 为便于广大投资者更深入全面地了解公司情况，公司定于 2024 年 10 月 28 日（星 期一）下午 15:00-16:30 在深圳证券交易所"互动易"平台"云访谈"栏目举行 2024 年 第三季度网上业绩说明会。本次业绩说明会将采用网络远程的方式举行，投资者可登陆 深圳证券交易所"互动易"平台（http://irm.cninfo.com.cn），进入"云访谈"栏目参与 本次业绩说明会。 北京怡和嘉业医疗 ...

Revenue and Profit - Revenue for the third quarter was RMB 219,915,135.08, a 10.51% increase year-over-year[2] - Net profit attributable to shareholders was RMB 32,744,656.32, up 21.78% compared to the same period last year[2] - Revenue for the first nine months was RMB 602,082,982.76, a 36.31% decrease year-over-year, primarily due to reduced market demand[5] - Total revenue for the period was 602,082,982.76 RMB, a decrease from the previous period's 945,302,594.29 RMB[14] - Net profit for the quarter was RMB 127.55 million, with a year-on-year increase of 46.7%[15] - Net profit attributable to the parent company was 971,585,919.43 RMB, up from 910,465,387.61 RMB[13] Assets and Liabilities - Total assets as of the end of the reporting period were RMB 3,243,476,467.71, an 11.13% increase from the end of the previous year[2] - Total assets increased to 3,243,476,467.71 RMB from 2,918,544,550.84 RMB[13] - Total liabilities rose to 436,840,395.44 RMB from 131,615,112.91 RMB[13] - Long-term equity investments increased by 1134.40% to RMB 157,317,520.08 due to increased external investments[5] - Long-term equity investments increased significantly to 157,317,520.08 RMB from 12,744,459.75 RMB[11] Cash Flow - Cash flow from operating activities for the first nine months was RMB 184,598,410.73, a 101.59% increase year-over-year[2] - Cash flow from operating activities for the quarter was RMB 184.60 million, an increase of 101.6% year-on-year[17] - Cash flow from investing activities for the quarter was negative RMB 615.29 million, a significant decrease compared to the positive RMB 94.96 million in the same period last year[18] - Cash flow from financing activities for the quarter was positive RMB 56.06 million, compared to negative RMB 134.40 million in the same period last year[18] - The company's cash and cash equivalents at the end of the quarter were RMB 296.74 million, a decrease of 27.0% compared to the beginning of the quarter[18] - Cash and cash equivalents decreased to 305,215,351.84 RMB from 670,354,040.76 RMB[11] Accounts Receivable and Inventory - Accounts receivable rose by 34.20% to RMB 145,711,610.81, driven by increased sales revenue at the end of the quarter[5] - Trade receivables increased to 145,711,610.81 RMB from 108,576,764.77 RMB[11] - Inventory decreased to 109,343,370.22 RMB from 118,014,141.74 RMB[11] Contract Liabilities and Other Income - Contract liabilities surged by 165.30% to RMB 74,115,283.93, mainly due to increased advance payments from customers[5] - Other income decreased by 65.67% to RMB 12,949,746.71 due to reduced software tax refunds[6] Government Subsidies and Tax Refunds - Government subsidies received during the reporting period amounted to RMB 564,133.00[3] - Tax refunds received decreased by 72.44% to RMB 33,720,467.89 due to reduced export tax refunds[6] Financial Income and Credit Impairment - Financial income increased by 38.93% to RMB -5,501,004.74, influenced by exchange rate fluctuations[5] - Credit impairment loss decreased by 33.83% to RMB -1,817,744.12 due to slower accounts receivable growth[6] Operating Costs and R&D Expenses - Total operating costs amounted to 507,037,954.75 RMB, down from 711,633,787.42 RMB in the previous period[14] - R&D expenses were 90,640,802.32 RMB, slightly lower than the previous period's 93,289,888.63 RMB[14] Shareholder Information - Zhuang Zhi holds 13.10% of the company's shares, totaling 11,736,608 shares[7] - Zhuhai Hexuan Investment Center holds 12.45% of the company's shares, totaling 11,155,686 shares[7] Comprehensive Income and Earnings Per Share - Total comprehensive income for the quarter was RMB 127.56 million, a decrease of 53.3% year-on-year[16] - Basic earnings per share for the quarter were RMB 1.399, a decrease of 66.9% compared to the same period last year[16] Cash Payments - Cash paid for goods and services decreased by 53.67% to RMB 251,751,417.95 due to reduced procurement expenses[6] - Cash paid for taxes decreased by 59.02% to RMB 45,171,889.79 due to reduced revenue scale[6] - Cash paid for dividends and interest decreased by 49.39% to RMB 65,795,750.00 due to reduced cash dividends and bank loan interest payments[6] - Cash paid for other financing activities increased by 1192.76% to RMB 56,880,831.26 due to share repurchase payments[6] Operating Profit - Operating profit for the quarter reached RMB 146.57 million, a decrease of 52.6% compared to the same period last year[15] Disposal of Fixed Assets - Cash received from disposal of fixed assets increased by 164.24% to RMB 449,214.35 due to changes in disposal gains[6]

具体内容详见公司同日披露于巨潮资讯网（www.cninfo.com.cn）上的《2024 年第三季度报告》。 北京怡和嘉业医疗科技股份有限公司 第三届监事会第十次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 北京怡和嘉业医疗科技股份有限公司（以下简称"公司"）第三届监事会第 十次会议于 2024 年 10 月 24 日在公司会议室以现场结合通讯方式召开，会议通 知已于 2024 年 10 月 18 日以书面、电子邮件方式发出并送达全体监事。会议由 公司监事会主席肖爱军先生召集并主持。本次会议应出席的监事 3 人，实际出席 的监事 3 人，其中监事孟晓英先生以通讯方式参加会议。公司董事会秘书列席本 次会议。本次监事会会议的召开符合有关法律、行政法规、部门规章、规范性文 件和《北京怡和嘉业医疗科技股份有限公司章程》（以下简称"《公司章程》"） 的规定。 二、监事会会议审议情况 经全体与会监事充分讨论，本次会议审议并通过了如下议案： 1、审议通过《关于公司 2024 年第三季度报告全文的议案》； 经审议，监事会认为公司《202 ...

证券代码：301367 证券简称：怡和嘉业 公告编号：2024-056 北京怡和嘉业医疗科技股份有限公司 第三届董事会第十次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 北京怡和嘉业医疗科技股份有限公司（以下简称"公司"）第三届董事会第十 次会议于 2024 年 10 月 24 日在公司会议室以现场结合通讯的方式召开，会议通 知已于 2024 年 10 月 18 日以书面、电子邮件方式发出并送达全体董事。本次会 议由公司董事长庄志先生召集并主持。本次会议应出席的董事 9 人，实际出席的 董事 9 人，其中董事周明钊先生、崔文立先生、TAN CHING（谈庆）先生、库 逸轩先生、厉洋先生、孙培睿先生以通讯方式参加会议。公司监事和高级管理人 员列席了本次会议。本次会议的召开符合有关法律、行政法规、部门规章、规范 性文件和《北京怡和嘉业医疗科技股份有限公司章程》（以下简称《" 公司章程》"） 的规定。 二、董事会会议审议情况 经全体与会董事充分讨论，本次会议审议并通过了如下议案： 1、审议通过《关于公司 2024 年第三季度报 ...

证券代码：301367 证券简称：怡和嘉业 公告编号：2024-055 北京怡和嘉业医疗科技股份有限公司 关于持股5%以上股东及其一致行动人 减持股份的预披露公告 公司股东能金有限公司及其一致行动人广州市金垣创业投资合伙企业（有限 合伙）、珠海合晅投资中心（有限合伙）及其一致行动人上海盛旻创业投资合伙 企业（有限合伙）和南京合灏创业投资企业（有限合伙）保证向本公司提供的信 息内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、合计持有本公司股份 6,127,120 股（占本公司总股本比例 6.84%）的股东 能金有限公司及其一致行动人广州市金垣创业投资合伙企业（有限合伙）计划在 自本减持计划公告之日起 15 个交易日后的 3 个月内以集中竞价方式或大宗交易 方式减持本公司股份累计不超过 2,667,156 股，占本公司总股本比例 3%（总股本 已剔除公司回购专用账户中的股份数量，下同）。 2、合计持有本公司股份 16,887,790 股（占本公司总股本比例 18.85%）的股 东珠海合晅投 ...